Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

biotech lab

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf immunotherapy candidate, OST-HER2, for pulmonary metastatic osteosarcoma, an aggressive type of bone cancer.

The data showed statistically significant positive final 2-year overall survival data in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.